Pyruvate, Spinal Fluid
Pyruvate is a central metabolite in carbohydrate metabolism, generated during glycolysis and linked to the tricarboxylic acid (TCA) cycle, amino acid metabolism, fatty acid β-oxidation, and the mitochondrial respiratory chain. The brain, which consumes approximately 40% of circulating glucose, is particularly dependent on efficient energy metabolism. Measurement of cerebrospinal fluid (CSF) pyruvate, especially in combination with lactate, provides key insights into neurological disorders of mitochondrial energy metabolism.
Elevated CSF pyruvate is seen in disorders such as Mitochondrial encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) and pyruvate dehydrogenase complex (PDHC) deficiency. Conversely, low pyruvate may occur in advanced mitochondrial disorders with diminished substrate availability. Importantly, interpretation of pyruvate must be coupled with lactate to calculate the lactate-to-pyruvate (L:P) ratio. A decreased L:P ratio (<10) suggests PDHC deficiency, while an elevated L:P ratio (>20) is characteristic of MELAS and other respiratory chain defects.
Clinical manifestations in these disorders may include seizures, developmental delay, ataxia, brain malformations, neuropathy, stroke-like episodes, and progressive neurodegeneration.
- As an aid in the diagnosis of mitochondrial and metabolic encephalopathies
- Monitoring disease progression and prognosis in mitochondrial disorders
Increased CSF pyruvate:
- MELAS (often with L:P ratio >20)
- Leigh syndrome
- Pyruvate dehydrogenase complex deficiency (with low L:P ratio)
- Lactic acidosis
- Stroke-like episodes
Decreased CSF pyruvate:
- Advanced mitochondrial disorders (e.g., Kearns–Sayre syndrome)
- Vitamin B1 (thiamine) deficiency
0.06-0.19 mmol/L
Spectrophotometric enzymatic assay; modern laboratories may use LC-MS/MS for more precise quantification.
Cerebrospinal fluid (CSF) collected in a sterile vial.
Stability
- Ambient: 24 hours
- Refrigerated: 5-7 days
- Frozen: 30 days
Comprehensive mitochondrial gene panel by next-generation sequencing (NGS), MT-TL1 mutation analysis, acylcarnitines, creatine kinase, lactate, uric acid, 5-methyltetrahydrofolate, CBC, comprehensive metabolic panel, urinalysis, and brain MRI (for structural abnormalities and stroke-like episodes).
2 to 5 days.
- Clin Biochem. 2013 May;46(7-8):694-7. [PMID: 23195138]
- Clin Biochem. 2015 Jun;48(9):631-2. [PMID: 25863113]
- Clin Chem. 2003 Mar;49(3):487-94. [PMID: 12600962]
- N Engl J Med. 2003;348:2656-2668. [PMID: 12826641]